< back to News

IMPACT-AML was prominently featured at the ERN-EuroBloodNet Board of Network Meeting, held during the European Hematology Association (EHA) Annual Congress 2026 in Stockholm, one of the most important international events in the field of haematology, drawing thousands of participants from across Europe and beyond. Convened within this setting, the meeting brought together leading experts, clinicians, researchers, patient representatives and policymakers to discuss key priorities for rare haematological diseases within the European healthcare landscape.

Prof. Giovanni Martinelli, Scientific Coordinator of IMPACT-AML and Professor at the Department of Medical and Surgical Sciences (DIMEC), University of Bologna, was invited to speak during Session 1: EU Action Plan for Rare Diseases, where he presented the vision, objectives and latest progress of the IMPACT-AML project.

During his speech, Prof. Martinelli highlighted how IMPACT-AML is contributing to the advancement of precision medicine in acute myeloid leukaemia (AML), specifically for the Relapsed/Refractory form (R/R AML), through a collaborative European approach. The project aims to improve patient outcomes by facilitating access to innovative therapies and clinical trials, while promoting the integration of cutting-edge molecular diagnostics and personalised treatment strategies into clinical practice.

A central topic of discussion was the growing importance of generating high-quality real-world evidence (RWE) to complement traditional clinical research. Participants emphasized the critical role of registries such as ENROL, particularly for advanced therapies and ultra-rare diseases, where conducting large randomized clinical trials may be challenging.

Within this context, IMPACT-AML was recognized as a key initiative supporting the collection of real-world data (RWD) through STREAM, the ENROL-based registry developed within the project. By systematically gathering clinical and molecular data from patients across Europe, STREAM aims to strengthen evidence generation, support personalised treatment decisions, contributing to reduce inequalities in AML care among European countries.

Prof. Martinelli also addressed the importance of evaluating treatment success beyond conventional clinical endpoints. He highlighted the increasing relevance of patient-reported outcome measures (PROMs) and quality-of-life (QoL) assessments in understanding the broader impact of innovative therapies on patients and their families and caregivers.

The session underscored the need for long-term follow-up programmes, capable of capturing the real-life benefits and challenges associated with new treatments. Participants discussed how quality-of-life data can support clinical decision-making, inform regulatory and reimbursement processes, and ultimately help ensure that innovation translates into meaningful improvements for patients.

The IMPACT-AML project also participated in the event by hosting a stand in the Collaboration Plaza, alongside EuroBloodNet.

The participation of IMPACT-AML in the ERN-EuroBloodNet Board of Network Meeting further reinforces the project’s commitment to fostering collaboration across Europe, advancing precision medicine, and generating the evidence needed to improve outcomes for patients living with R/R AML.